Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Nuvo Pharmaceuticals Inc MRVFF

Healthcare Drug Manufacturers - Specialty & Generic
Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets. see more

Recent & Breaking News (OTCQX:MRVFF)

Nuvo Research® Announces Scientific Presentations at Annual Painweek 2013 Meeting

Canada NewsWire September 5, 2013

Nuvo Research® announces that FDA has accepted Pennsaid® 2% new drug application for review

Canada NewsWire August 22, 2013

Nuvo Research® announces lawsuit against Mallinckrodt

Canada NewsWire August 21, 2013

Nuvo announces Mallinckrodt submits PK study report in response to PENNSAID® 2% FDA complete response letter

Canada NewsWire August 15, 2013

Nuvo Research announces 2013 second quarter results

Canada NewsWire July 31, 2013

Nuvo Research® announces update to Pennsaid® 2% Complete Response Letter

Canada NewsWire July 23, 2013

Paladin Labs and Nuvo Research(R) Announce Completion of the Loan Arrangement

Marketwired July 10, 2013

Paladin Labs and Nuvo Research(R) Announce Completion of the Loan Arrangement

Marketwired July 10, 2013

Nuvo Research® and Paladin Labs announce completion of the loan arrangement

Canada NewsWire July 10, 2013

Nuvo Research® and Paladin Labs announce completion of the loan arrangement

PR Newswire July 10, 2013

Galen to acquire U.S. rights for Synera® from Nuvo Research®

Canada NewsWire July 10, 2013

Galen to acquire U.S. rights for Synera® from Nuvo Research®

PR Newswire July 10, 2013

Nuvo Research Announces Director Election Results of its Annual General Meeting

Canada NewsWire June 18, 2013

Nuvo Research Announces Director Election Results of its Annual General Meeting

PR Newswire June 18, 2013

Nuvo Research(R) and Paladin Labs Announce Amendment to May 2012 Loan Arrangement

Marketwired June 17, 2013

Nuvo Research(R) and Paladin Labs Announce Amendment to May 2012 Loan Arrangement

Marketwired June 17, 2013

Nuvo Research® and Paladin Labs announce amendment to May 2012 loan arrangement

Canada NewsWire June 17, 2013

Nuvo Research® and Paladin Labs announce amendment to May 2012 loan arrangement

PR Newswire June 17, 2013

Nuvo Research announces scientific presentations at the Annual Meeting of the American College of Sports Medicine

PR Newswire May 30, 2013

Nuvo Research announces scientific presentations at the Annual Meeting of the American College of Sports Medicine

Canada NewsWire May 30, 2013